H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP: